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Human melanocortin MC1 and MC3 receptors expressed on C-20/A4 chondrocytes exhibit 
chondroprotective and anti-inflammatory effects when activated by melanocortin peptides. 
Nearly 9 million people in the UK suffer from osteoarthritis, and bacterial infections play a 
role in its development. Here, we evaluate the effect of a panel of melanocortin peptides with 
different selectivity for human melanocortin MC1 (α-MSH, BMS-470539 dihydrochloride) 
and MC3 receptors ([DTrp8]-γ-MSH, PG-990) and C-terminal peptide α-MSH11-13(KPV), on 
inhibiting LPS-induced chondrocyte death, pro-inflammatory mediators and induction of 
anti-inflammatory proteins. C-20/A4 chondrocytes were treated with a panel of melanocortin 
peptides prophylactically and therapeutically in presence of LPS (0.1 µg/ml). The 
chondroprotective properties of these peptides determined by cell viability assay, RT-PCR, 
ELISA for detection of changes in inflammatory markers (IL-6, IL-8 and MMP-1, -3 and -13) 
and western blotting for expression of the anti-inflammatory protein heme-oxygenase-1. C-
20/A4 expressed human melanocortin MC1 and MC3 receptors and melanocortin peptides 
elevated cAMP. LPS stimulation caused a reduction in C-20/A4 viability, attenuated by the 
human melanocortin MC1 receptor agonist BMS-470539 dihydrochloride, and MC3 receptor 
agonists PG-990 and [DTrp8]-γ-MSH. Prophylactic and therapeutic regimes of [DTrp8]-γ-
MSH significantly inhibited LPS-induced modulation of cartilage-damaging IL-6, IL-8, 
MMPs -1,-3 and -13 mediators both prophylactically and therapeutically, whilst human 
melanocortin MC1 and MC3 receptor agonists promoted an increase in HO-1 production. In 
the presence of LPS, activation of human melanocortin MC1 and MC3 receptors provided 
potent chondroprotection, upregulation of anti-inflammatory proteins and downregulation of 
inflammatory and proteolytic mediators involved in cartilage degradation, suggesting a new 
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The bacterial endotoxin lipopolysaccharide (LPS) contributes to the development of 
Osteoarthritis (OA) and intra-articular infections (Mue et al., 2013; Huang et al., 2016) via 
activation of Toll-Like Receptors. Activation, results in rapid expression of a variety of pro-
inflammatory cytokines and cytotoxic mediators, destructive matrix metalloproteinases 
(MMPs) and reactive oxygen species (ROS) (Ziskoven et al., 2010; Schmal et al., 2016). 
Chondrocytes directly activated by LPS up-regulate expression of pro-inflammatory 
cytokines including Interleukin(IL)-6, IL-8 and cartilage destructive proteases including 
matrix metalloproteinases (MMPs) -1,-3,-13, increasing chondrocyte death (Capsoni et al., 
2015) and disrupting chondrocyte biosynthetic abilities compromising cartilage stability 
(Huang and Kraus, 2016). 
 
Melanocortin receptors are G-Protein-coupled receptors (GPCR’s), positively coupled to 
adenylate cyclase activating the cAMP signalling pathway (Patruno et al., 2018). They 
display diverse biological functions ranging from modulating inflammatory pathways, skin 
pigmentation, energy metabolism/food intake and sexual health (Getting 2006; Loram et al., 
2015). Over the past two decades, in addition to studies with the parent hormone 
Adrenocorticotrophic hormone-(ACTH) (Getting et al., 2009) and alpha-melanocyte 
stimulating hormone-(α-MSH) (Getting et al., 2009; Horrell et al., 2016), several selective 
peptides have been developed including the human melanocortin MC3 receptor agonist 
[DTrp8]-γ-MSH (Grieco et al., 2000), human melanocortin MC1 receptor agonist BMS-
470539 dihydrochloride (Leoni et al., 2010), enabling a clearer understanding of the role of 
these receptors in modulating inflammation in arthritis and stroke (Getting et al., 2006; 
Holloway et al., 2015). The importance of targeting these receptors in inflammatory models, 
has been demonstrated by using naturally occurring melanocortin MC1 receptor mutants 
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(recessive yellow e/e mice) (Leoni et al., 2010) and gene deletion of melanocortin MC3 
receptor in mice (Getting et al., 2006), demonstrating exacerbation of the host inflammatory 
response (Patel et al., 2010; Holloway et al., 2015).  
 
Although the role of melanocortin peptides has been established in many models of disease 
only a few studies highlight the role of melanocortin peptides in OA models providing 
chondroprotection, inhibition of pro-inflammatory markers and induction of anti-
inflammatory proteins. These studies demonstrate that melanocortin peptides repress NF-κB 
pathways in the human sarcoma cell line-(HTB-94) downregulating transcriptional activation 
of MMPs (Yoon et al., 2008), whilst, in C-20/A4 chondrocytes, melanocortin peptides 
provide chondroprotection modulating MMPs, IL-6 and IL-8 (Kaneva et al., 2012). These 
findings identified in cell-lines and confirmed in primary cells and tissue, with α-MSH 
inhibiting IL-1β and Tumour necrosis factor alpha-(TNF-α) mRNA levels in human articular 
chondrocytes (Capsoni et al., 2015), and IL-1β, IL-6 and IL-8 from primary bovine 
chondrocytes and cartilage (Kaneva et al., 2014). In this study, we determined whether LPS 
activation caused expression of IL-1β, IL-6, IL-8, MMP1, MMP3 and MMP13 and whether 
melanocortin peptides increased the anti-apoptotic protein, heme-oxygenase-1-(HO-1) in C-
20/A4 chondrocytes. We also determined if targeting human melanocortin MC1 and MC3 
receptors using the peptides α-MSH, BMS-470539 dihydrochloride, [DTrp8]-γ-MSH, PG-
990 and C-terminal peptide α-MSH11-13(KPV) would modulate the pro-inflammatory and 
catabolic effects of LPS, prophylactically and therapeutically, whilst inducing the pro-
resolving anti-inflammatory protein HO-1, thus demonstrating a role for these peptides in 





2. Materials and methods 
 
2.1. Materials   
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium), lipopolysaccharide (E. coli 
serotype 111.60) (LPS) and α-MSH were purchased from Sigma-Aldrich (Poole, Dorset, 
UK), BMS-470539 dihydrochloride purchased from Tocris Bioscience (Bristol, UK), C-
terminal peptide α-MSH11-13 (KPV) were purchased from Bachem (UK) Ltd (Saint Helens, 
UK.), [DTrp8]-γ-MSH and PG-990 synthesised by Prof. P. Grieco (University of Naples, 
Italy)  (Grieco et al., 2000; Carotenuto et al., 2015). Primers IL6, IL8, MMP1, MMP3 and 
MMP13 purchased from Eurofins Genomics. Anti-HO-1 antibody purchased from 
Enzolifesciences. ELISA kits purchased from R & D Systems (Oxon, UK).  
 
2.2. Cell culture 
The human chondrocyte cell-line C-20/A4, derived from juvenile costal chondrocytes, a kind 
gift of Prof. M.B. Goldring, (Hospital for Special Surgery, New York, USA) (Kaneva et al., 
2012) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% (v/v) heat-inactivated Foetal Calf Serum (FCS), 1% (v/v) L-glutamine and 
Penicillin/Streptomycin (100.0 U/ml and 100.0 µg/ml), incubated at 37oC in a humidified 
atmosphere supplied with 5% CO2 until 80% confluent, as previously described (Kaneva et 
al., 2012). Prior to experimentation, FCS concentration was reduced to 1% (v/v) (DMEM 
supplemented with 1% (v/v) FCS, 1% (v/v) L-glutamine and Penicillin/Streptomycin (100.0 
U/ml and 100.0 µg/ml)) for 24 h and all subsequent experiments were performed under these 




2.3. C-20/A4 chondrocyte stimulation/ treatment 
C-20/A4 cells were treated either 30 min prior to (prophylactic regime) or 2 h post 
(therapeutic regime) 0.1 µg/ml LPS (E. coli; 111.60) stimulation (concentration selected from 
preliminary experiments), Phosphate Buffered Saline (PBS) (control), pan human 
melanocortin MC1 receptor agonist α-MSH (3.0 µg/ml) (Kaneva et al., 2012), human 
melanocortin MC3 receptor agonist [DTrp8]-γ-MSH (3.0 µg/ml) (Kaneva et al., 2012), KPV 
(4.0 µg/ml) (Getting et al., 2009), human melanocortin MC1 receptor agonist BMS-470539 
dihydrochloride (10.0 µg/ml) (Leoni et al., 2010), or selective human melanocortin MC3 
receptor agonist PG-990 (3.0 µg/ml) (Carotenuto et al., 2015). Receptor nomenclature for 
melanocortin receptors was used in accordance with the IUPHAR receptor database. 
 
2.4 Molecular analysis 
2.4.1. RT-PCR analysis 
C-20/A4 chondrocyte RNA extracted and isolated using the NucleoSpin® RNA II Kit 
(Macherey-Nagel, Duren, Germany) as previously described (Kaneva et al., 2012).  Briefly, 
RNA concentrations were determined using a NanoDrop® ND-1000 UV-Vis 
Spectrophotometer (A260nm/280nm: 1.9-2.1). cDNA was synthesised by taking 1.0 µg of DNase-
treated total RNA, Oligo(dT), Random Primers and RNase inhibitor in a total volume of 20.0 
µl using the Improm II Reverse Transcription System (Promega, UK). 2.0 µl aliquots of the 
cDNA (in a final volume of 25 µl) were used as a template for PCR amplification using 
specific primer pairs for IL6, IL8, MMP1, MMP3 and MMP13 with the GoTaq® Green 
Mastermix system (Promega, UK). Oligonucleotide primers for human β-actin were used as a 
control. The oligonucleotide primer sequences used shown in Table 1. The PCR parameters 
were as follows: initial denaturation for 5 min at 95°C, followed by 25 cycles of denaturation 
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(95°C for 60 s), annealing (53.7-64.8°C, depending on the primers used for 90 s), extension 
(72°C for 90 s), with a single final extension of 72°C for 10 min. Amplification products 
were separated by agarose gel electrophoresis and stained with ethidium bromide. 
Densitometry analysis was performed using Image J software (NIH, Bethesda, Maryland, 
USA). 
 
2.4.2. Intracellular cAMP accumulation 
Intracellular cAMP in C-20/A4 chondrocytes was determined by Enzyme Immunoassay 
(RPN225, GE Healthcare, Amersham, UK). 2 x 105 chondrocytes·per well were seeded into a 
96-well plate as previously described (Getting et al., 2005; Kaneva et al., 2012) and incubated 
for 24 h at 37oC in a humidified incubator supplied with 5% CO2 to allow cell adhesion. 
Medium was discarded and chondrocytes were treated with the panel of melanocortin 
peptides, 3.0 µM forskolin (used as a positive control) or PBS (negative control) for 30 min 
in the presence of 1 mM 3-isobutyl-1-methylxanthine (IBMX; Sigma-Aldrich, UK). Adhered 
cells were lysed according to the manufacturer’s guidelines and intracellular cAMP 
concentration was determined (Lam et al., 2005a; Kaneva et al., 2012).  
 
2.4.3. Western blotting 
C-20/A4 chondrocytes protein expression of HO-1 was determined as previously described 
(Lam et al., 2005b).  Following electrophoresis in a 10% SDS-polyacrylamide gel, proteins 
were transferred onto a nitrocellulose membrane, blocked overnight in 5% non-fat milk 
solution in Tris-HCl buffered saline (TBS) pH 7.5 containing 0.1% (v/v) Tween-20 and then 
incubated with either rabbit anti-HO-1 antibody (1:2000, Enzolifesciences, UK) or mouse 
anti-α-Tubulin antibody (1:2000, Sigma-Aldrich, Poole, Dorset, UK) in 5% non-fat milk 
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solution.  Blots were washed in TBS prior to the addition of a secondary goat anti-rabbit 
horseradish peroxidase (HRP)-conjugated IgG antibody (1:2000, DakoCytomation, USA) or 
goat anti-mouse HRP-conjugated IgG antibody (1:2000, DakoCytomation, USA) and signal 
was detected by enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL, USA). 
Densitometry analysis performed using Image J software (NIH, Bethesda, Maryland, USA). 
 
2.5. Biochemical and cell viability analysis 
2.5.1. Cytokine and MMP quantification by ELISA 
Human IL-1β, IL-6, IL-8, MMP-1, MMP-3 and MMP-13 concentrations in C-20/A4 
chondrocyte cell-free supernatants following LPS and peptide treatments were determined 
using commercially available ELISA kits (R&D Systems Europe Ltd, Oxford, UK) according 
to the manufacturer’s instructions.  
 
2.5.2. MTT assay 
Cell viability was determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium 
(MTT) assay, as previously described (Kaneva et al., 2012). Briefly, C-20/A4 cells were 
plated at 1.5 x 106 cells/well in 24-well plates and allowed to adhere overnight prior to serum 
reduction. Cells were treated as described in the individual figure legends. Media was 
aspirated and MTT solution added for 2h, chondrocytes were then incubated at 37°C in a 
humidified chamber with 5% CO2. Following incubation with the MTT solution, the 
supernatant was replaced with DMSO and samples incubated for 15 min, 100 µl was then 




2.5.3. Caspase-Glo 3/7 apoptosis assay. 
Apoptosis was determined by measuring caspase-3 and -7 activity following cell stimulation 
as detailed above (see section 2.3. C-20/A4 chondrocyte stimulation/ treatment). Briefly, C-
20/A4 chondrocytes were plated at 2.0 x103 cells per well in 96 well plates, and 100 µl of 
Caspase-GLO 3/7 Reagent (Promega, UK) was added to each well and incubated at room 




All data are reported as mean ± S.E.M of n observations performed in triplicate unless 
otherwise stated. Statistical evaluation was performed using analysis of variance ANOVA 
(Prism GraphPad Software) incorporating either Dunnetts’ or Bonferroni’s Multiple 
Comparison tests to allow for post-hoc analyses with a probability *P≤ 0.05; **P≤ 0.01; 






3.1 C-20/A4 chondrocytes express functionally active human melanocortin MC1 and 
MC3 receptors 
RT-PCR confirmed endogenous expression of the human melanocortin MC1 and MC3 
receptors in C-20/A4 cells (Data not shown). Receptor functionality was determined by 
cAMP accumulation, direct adenylate cyclase stimulator, Forskolin (3.0 µM) caused a 7.5-
fold increase in cAMP over control.  A panel of melanocortin peptides were used to 
determine receptor functionality by measuring cAMP accumulation. α-MSH (3.0 µg/ml) and 
[DTrp8]-γ-MSH (3.0 µg/ml) caused an elevation in cAMP (Data not shown).  Whilst, the 
highly selective human melanocortin MC1 receptor agonist BMS-470539 dihydrochloride 
(10.0 µg/ml) caused a 2.0-fold increase and selective human melanocortin MC3 receptor 
agonist PG-990 (3.0 µg/ml) caused a 3.7-fold increase in intracellular cAMP accumulation 
(Table 2). 
 
3.2. Melanocortin peptides provide chondroprotection against LPS-induced activation 
of chondrocytes 
Previous studies indicate that melanocortin peptides can modulate TNF-α induced cell death 
(Kaneva et al., 2012); here we wanted to determine the effect of the melanocortin peptides in 
the presence of LPS. LPS stimulation caused a 13.0% (P≤0.001 vs untreated control) 
reduction in cell viability compared to untreated control (Table 3). Prophylactic treatment 
with α-MSH, [DTrp8]-γ-MSH and KPV significantly protected against LPS-induced cell 
death by causing a 74.0%, 39.0% and 38.0% (P≤0.001 vs LPS) increase in cell viability, 
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respectively, compared to LPS stimulation. To evaluate if this effect was via human 
melanocortin MC1 receptor and/or human melanocortin MC3 receptor, the selective human 
melanocortin MC1 receptor and human melanocortin MC3 receptor agonists BMS-470539 
dihydrochloride and PG-990 were evaluated and caused a 26.0% and 41.0% increase in cell 
viability, respectively (P≤0.001 vs LPS). Therapeutic treatment with α-MSH, [DTRP8]-γ-
MSH and PG-990 caused a 22.0%, 18.0% and 21.0% (P≤0.001 vs LPS) increase in cell 
viability, respectively above LPS stimulation. Whilst KPV and BMS-470539 dihydrochloride 
increased cell viability above LPS stimulation by 14.0% and 13.0% (P≤0.01 vs LPS) 
respectively, returning values to basal levels (Table 3). Previous studies have shown that 
melanocortin peptides can modulate TNF-α induced caspase 3/7 activity (Kaneva et al., 
2012); here we ascertained the effect of the melanocortin peptides in the presence of LPS. 
LPS stimulation caused a significant increase in caspase 3/7 activity compared to untreated 
control (P≤0.001 vs untreated control) (Fig. 1A-B). Prophylactic treatment with α-MSH, 
[DTrp8]-γ-MSH and KPV significantly reduced the caspase 3/7 activity by 15.9%, 7.3% and 
9.7% (P≤0.01 vs LPS) respectively compared to LPS stimulation. To evaluate if this effect 
was via human melanocortin MC1 receptor and/or human melanocortin MC3 receptor, the 
selective human melanocortin MC1 receptor and human melanocortin MC3 receptor agonists 
BMS-470539 dihydrochloride and PG-990 were evaluated and caused a 7.1% and 8.0% 
decrease in caspase 3/7 activity, respectively (P≤0.01 vs LPS). Therapeutic treatment with α-
MSH, [DTRP8]-γ-MSH and PG-990 caused an 8.4%, 9.0% and 11.3% (P≤0.001 vs LPS) 
decrease in caspase 3/7 activity following LPS stimulation. Whilst KPV and BMS-470539 
dihydrochloride decreased caspase 3/7 activity by 8.6% and 8.9% (P≤0.01 vs LPS) 




3.3. Prophylactic and therapeutic treatment of C-20/A4 chondrocytes with α-MSH, 
[DTrp8]-γ-MSH and KPV reduced LPS-induced IL-1β, IL-6 and IL-8 production.  
The pro-inflammatory cytokines IL-1β, IL-6 and IL-8 play an important role in the 
development of OA (Kaneva et al., 2012, 2014; Ni et al., 2019); here we determined the 
effects of LPS on C-20/A4 chondrocytes on these markers. LPS stimulation caused a 
significant 3.1-fold and 3.0-fold upregulation of IL6 and IL8 mRNA levels respectively 
(P≤0.001 vs untreated control; Fig. 2B-C). Prophylactic treatment with α-MSH abrogated 
IL6 gene expression and significantly reduced IL8 gene expression by 5.0-fold ±0.05 
(P≤0.001 vs LPS). [DTrp8]-γ-MSH abrogated both IL6 and IL8 gene expression, whilst, KPV 
abrogated IL6 gene expression and significantly reduced IL8 gene expression by 10.0-fold 
±0.03 (P≤0.001 vs LPS). Therapeutic treatment with α-MSH caused a 1.7-fold ±0.02 and 1.2-
fold ±0.04 decrease in LPS-induced IL6 and IL8 gene expression respectively (P≤0.01, 
P≤0.001 vs LPS), whilst [DTrp8]-γ-MSH caused a significant decrease in LPS-induced IL6 
and IL8 gene expression by a 3.4-fold ±0.05 and 3.8-fold ±0.04 respectively (P≤0.001 vs 
LPS). The C-terminal peptide KPV caused a 1.9-fold ±0.05 and 1.2-fold ±0.04 decrease in 
LPS-induced IL6 and IL8 gene expression respectively (P≤0.01, P≤0.001 vs LPS; Fig. 2A-C). 
Following observation of a reduction in IL6 and IL8 gene expression by the melanocortin 
peptides, ELISAs were performed to determine effects on protein level. LPS (0.1 µg/ml) 
stimulation caused a significant increase in IL-1β, IL-6 and IL-8 protein release at 6h, with 
33 ±0.5 (pg•mL-1), 258 ±7.1 (pg•mL-1) and 378 ±1.8 (pg•mL-1) respectively above control 
levels (P≤0.001 vs untreated control) (Table 4). Prophylactic treatment with α-MSH, 
[DTrp8]-γ-MSH and KPV caused an 45.5% ±7.8, 54.5% ±5.3 and 45.5% ±8.9 reduction in 
IL-1β respectively (P≤0.01 vs LPS), 84.0% ±3.0, 88.0% ±5.4 and 77.0% ±7.7 reduction in 
IL-6 respectively (P≤0.001 vs LPS). α-MSH and [DTrp8]-γ-MSH caused a 77.0% ±6.9 and 
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68.0% ±7.0 reduction in IL-8 protein release respectively (P≤0.001 vs LPS), whilst KPV 
failed to significantly reduce IL-8 levels when administered prophylactically. Following 
determination that prophylactic treatment with certain melanocortin peptides resulted in 
significant reductions in the expression of IL-1β, IL-6 and IL-8, their efficacy in a therapeutic 
scenario was determined. α-MSH, [DTrp8]-γ-MSH and KPV caused a 33.3% ±5.5, 54.5% 
±6.0 and 42.4% ±6.3 reduction in IL-1β release (P≤0.01 vs LPS), 74.0% ±4.0, 81.0% ±1.1 
and 22.0% ±1.2 reduction in IL-6 release (P≤0.001 vs LPS), α-MSH and [DTrp8]-γ-MSH 
caused a 59.0% ±4.3 and 76.0% ±4.2 reduction respectively in IL-8 (P≤0.001 vs LPS), whilst 
KPV failed to inhibit IL-8 protein release when administered therapeutically (Table 4).  
 
3.4. Effect of prophylactic and therapeutic treatment of α-MSH, [DTrp8]-γ-MSH and 
KPV on MMP1, MMP3 and MMP13 gene expression and protein release from LPS 
activated C-20/A4 chondrocytes 
MMP-1, MMP-3 and MMP-13 play an important role in the pathogenesis of OA 
(Kannengiesser et al., 2008; Getting et al., 2009; Kaneva et al., 2012), the effect of LPS 
stimulation of C-20/A4 chondrocytes on these markers was determined. Chondrocytes were 
stimulated with LPS and MMP1, MMP3 and MMP13 gene expression and protein release 
determined at 6h post stimulation.  LPS (0.1 µg/ml) stimulation caused a 27.0-fold ±0.05, 
2.0-fold ±0.01 and 1.7-fold ±0.04 increase in MMP1, MMP3 and MMP13 mRNA levels 
respectively (P≤0.001 vs untreated control) (Fig. 3B-D). α-MSH, [DTRP8]-γ-MSH and KPV 
treatment on gene expression was determined both prophylactically and therapeutically. 
Prophylactic treatment with α-MSH, [DTRP8]-γ-MSH and KPV abrogated MMP1 gene 
expression, whilst, therapeutic treatment with α-MSH, [DTRP8]-γ-MSH and KPV 
significantly decreased MMP1 gene expression by 27.0-fold ±0.02, 27.0-fold ±0.05 and 27.0-
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fold ±0.05 (P≤0.001 vs LPS) respectively (Fig. 3B). Prophylactic treatment with α-MSH and 
[DTRP8]-γ-MSH completely abrogated LPS-induced MMP3 gene expression, whilst, KPV 
caused a 1.0-fold ±0.02 decrease in MMP3 mRNA level (P≤0.05 vs LPS) (Fig. 3C). 
Therapeutic treatment with α-MSH decreased MMP3 mRNA level by 8.0-fold ±0.05 and 
[DTRP8]-γ-MSH completely abrogated LPS-induced MMP3 mRNA gene expression 
(P≤0.001 vs LPS). KPV had no effect on MMP3 gene expression following both prophylactic 
and therapeutic administration (Fig. 3C). Prophylactic treatment with α-MSH, [DTrp8]-γ-
MSH and KPV completely abrogated LPS-induced MMP13 gene expression (Fig. 3D), as did 
therapeutic treatment with [DTrp8]-γ-MSH. Therapeutic treatment with α-MSH and KPV 
significantly down-regulated MMP13 gene expression by 8.5-fold ±0.02 and 34.0-fold ±0.05 
(P≤0.001 vs LPS) respectively (Fig. 3D). Since, certain melanocortin peptides were able to 
completely abrogate or reduce MMP1, MMP3 and MMP13 gene expression, their effect was 
determined at protein level by ELISA. LPS stimulation caused an increase in MMP-1, MMP-
3 and MMP-13 protein release at 6h, with 988 ±1.8 (pg•mL-1), 408 ±2.2 (pg•mL-1) and 149 
±1.8 (pg•mL-1) respectively (P≤0.001 vs untreated control) (Table 4). Prophylactic treatment 
with α-MSH, [DTRP8]-γ-MSH and KPV caused a 44.0% ±3.1, 90.0% ±4.2 and 29.0% ±4.9 
(P≤0.001 vs LPS) reduction respectively in LPS-induced MMP-1, whilst, a 73.0% ±3.6, 
73.0% ±3.5 and 71.0% ±3.1 (P≤0.001 vs LPS) reduction respectively was observed for 
MMP-3, and a 66.0% ±6.1, 72.0% ±6.3 and 49.0% ±6.5 (P≤0.001 vs LPS) reduction for 
MMP-13 protein release (Table 4). Following determination that prophylactic treatment of 
the melanocortin peptides resulted in significant reductions in MMP-1, MMP-3 and MMP-13 
protein release, their effect when administered therapeutically was determined. α-MSH, 
[DTrp8]-γ-MSH and KPV caused a 69.0% ±5.6, 97.0% ±6.7 and 66.0% ±8.2 (P≤0.001 vs 
LPS) reduction in LPS-induced MMP-1 protein release, with a 15.0% ±2.3, 90.0% ±2.2 and 
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13.0% ±2.2 reduction in MMP-3 (P≤0.001, P≤0.001 vs LPS)  and a 60.0% ±1.3, 74.0% ±1.1 
and 60.0% ±4.2 reduction in MMP-13 respectively (P≤0.001 vs LPS) (Table 4). 
 
3.5. Melanocortin peptides induce the pro-resolving protein HO-1 
Since, melanocortin peptides inhibited both pro-inflammatory and tissue destructive 
mediators, we next evaluated their effect on their ability to induce the anti-inflammatory 
protein HO-1. LPS stimulation caused a 1.9-fold ±0.01 decrease in HO-1 production 
(P≤0.001 vs untreated control), whilst, prophylactic treatment with α-MSH, [D-Trp8]-γ-MSH 
and KPV caused a 6.1-fold ±0.09, 7.9-fold ±0.08 and 4.1-fold ±0.06 increase respectively 
(P≤0.001 vs LPS) abrogating the inhibitory effect of LPS and increasing expression of HO-1 
above that of the control (Fig. 4B). Therapeutic treatment with α-MSH, [DTRP8]-γ-MSH and 
KPV caused a 3.1-fold ±0.003, 3.1-fold ±0.03 and 2.7-fold ±0.06 increase respectively 
(P≤0.001 vs LPS; Fig. 4B). 
 
3.6. Prophylactic and therapeutic effect of the selective human melanocortin MC1 and 
MC3 receptor agonists on IL-1β, IL-6 and IL-8 gene expression and protein release in 
LPS activated chondrocytes  
Following identification of the chondroprotective, anti-inflammatory and pro-resolving 
properties of α-MSH, [DTrp8]-γ-MSH and KPV vs LPS activated chondrocytes, we next 
determined if human melanocortin MC1 receptor and /or human melanocortin MC3 receptor 
was responsible for eliciting these effects using the selective human melanocortin MC1 
receptor agonist BMS-470539 dihydrochloride and selective human melanocortin MC3 
receptor agonist PG-990 on pro-inflammatory cytokine release. Prophylactic treatment with 
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BMS-470539 dihydrochloride significantly decreased LPS-induced IL6 and IL8 gene 
expression by a 30.0-fold ±0.07 and 10.2-fold ±0.07 (P≤0.001 vs LPS), whilst, therapeutic 
treatment with BMS-470539 dihydrochloride caused a 15.0-fold ±0.05 and 30.5-fold ±0.01 
decrease in LPS-induced IL6 and IL8 gene expression respectively (P≤0.001 vs LPS; Fig. 5B-
C). Prophylactic treatment with PG-990 caused a 30.0-fold ±0.04 and 10.2-fold ±0.01 
decrease in LPS-induced IL6 and IL8 gene expression respectively (P≤0.001 vs LPS), whilst, 
therapeutic treatment displayed significant reductions in LPS-induced IL6 and IL8 mRNA 
levels by a 30.0-fold ±0.01 and 30.5-fold ±0.02 respectively (P≤0.001 vs LPS; Fig. 4B-C). At 
the protein level, LPS stimulation caused a significant increase in IL-1β, IL-6 and IL-8 
protein release at 6h, with 33 ±0.5 (pg•mL-1), 258 ±7.1 (pg•mL-1) and 378 ±1.8 (pg•mL-1) 
(P≤0.001 vs untreated control) respectively above control levels (Table 4). Prophylactic 
treatment with BMS-470539 dihydrochloride and PG-990 caused a 3.0% ±4.0 (n.s. vs LPS) 
and 45.5% ±6.1 (P≤0.01 vs LPS) reduction in LPS-induced IL-1β; 41.0% ±1.2 and 81.0% 
±2.9 (P≤0.001 vs LPS) reduction in LPS-induced IL-6, and a, 58.0% ±5.2 and 89.0% ±4.4 
reduction respectively for LPS-induced IL-8 release (P≤0.001 vs LPS) (Table 4). Following 
determination that prophylactic administration of the selective melanocortin peptides results 
in significant reductions in the secretion of IL-1β, IL-6 and IL-8, their effect therapeutically 
was determined. BMS-470539 dihydrochloride and PG-990 caused a 3.0% ±2.8 (n.s. vs LPS) 
and 54.5% ±4.7 (P≤0.01 vs LPS) reduction in LPS-induced IL-1β; 21.0% ±3.1 and 58.0% 
±4.4 reduction in LPS-induced IL-6 protein release respectively (P≤0.01; P≤0.001 vs LPS) 
and a 21.0% ±1.9 and 19.0% ±7.2 reduction respectively in IL-8 release (P≤0.01, P≤0.001 vs 




3.7. Prophylactic and therapeutic effect of the selective human melanocortin MC1 and 
MC3 receptor agonists on MMP-1, MMP-3 and MMP-13 gene expression and protein 
release from LPS-activated chondrocytes 
Since, the panel of melanocortin peptides were able to completely abrogate or reduce pro-
inflammatory cytokine release at gene expression and protein levels, the effects of the 
selective melanocortin peptides BMS-470539 dihydrochloride and PG-990 on MMP-1, 
MMP-3 and MMP-13 gene expression and protein release was investigated prophylactically 
and therapeutically. Prophylactic treatment with BMS-470539 dihydrochloride significantly 
decreased MMP1 gene expression by 1.6-fold ±0.05, whilst, PG-990 abrogated MMP1 gene 
expression (P≤0.001 vs LPS) (Fig. 6B). BMS-470539 dihydrochloride significantly reduced 
MMP3 gene expression by 1.3-fold ±0.02, whilst, PG-990 abrogated MMP3 gene expression 
(P≤0.001 vs LPS) (Fig. 6C). BMS-470539 dihydrochloride significantly reduced MMP13 
mRNA level by 2.4-fold ±0.06 (P≤0.001 vs LPS), whilst, PG-990 again completely abrogated 
MMP13 gene expression (Fig. 6D). Therapeutic evaluation of BMS-470539 dihydrochloride 
showed a decrease of MMP1, MMP3 and MMP13 gene expression by 21.0-fold ±0.03, 2.4-
fold ±0.06 and 2.4-fold ±0.05 respectively, whilst, PG-990 reduced MMP1, MMP3 and 
MMP13 gene expression by 21.0-fold ±0.01, 2.4-fold ±0.01 and 2.4-fold ±0.02 respectively 
(P≤0.001 vs LPS) (Fig. 6B-D). At the protein level, LPS stimulation caused a significant 
increase in MMP-1, MMP-3 and MMP-13 protein release at 6 h (Table 4). Prophylactic 
treatment with BMS-470539 dihydrochloride reduced MMP-1, MMP-3 and MMP-13 protein 
release by 9% ±5.5, 72.0% ±3.9 and 61.0% ±6.5 respectively, whilst, PG-990 reduced MMP-
1, MMP-3 and MMP-13 protein release by 29.0% ±1.9, 33.0% ±3.1 and 68.0% ±6.7 
respectively (P≤0.01, P≤0.001 vs LPS) (Table 4). Therapeutic treatment with the selective 
melanocortin peptides BMS-470539 dihydrochloride reduced LPS-induced MMP-1 and 
MMP-13 protein release by 69.0% ±2.3*** and 59.0% ±1.2*** respectively but did not 
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significantly inhibit MMP-3 protein release (P≤0.001 vs LPS). PG-990 reduced MMP-1, 
MMP-3 and MMP-13 protein release by 77.0% ±4.7, 57.0% ±2.5 and 72.0% ±1.3 
respectively (P≤0.01, P≤0.001 vs LPS) (Table 4).  
 
3.8. Determination of whether the selective human melanocortin MC1 and MC3 
receptor agonists induce the pro-resolving protein HO-1 when administered either 
prophylactically or therapeutically.  
In the final section of this study, we evaluated whether the selective human melanocortin 
MC1 receptor agonist BMS-470539 dihydrochloride and the selective human melanocortin 
MC3 receptor agonist PG-990 could induce HO-1 expression. Fig. 7 reports the data obtained 
at 6h for both prophylactic and therapeutic treatment. LPS caused a 1.7-fold ±0.05 decrease 
in HO-1 expression (P≤0.01 vs untreated control), whilst, prophylactic treatment of BMS-
470539 dihydrochloride and PG-990 caused a 2.1-fold ±0.06 and 3.1-fold ±0.05 (P≤0.001 vs 
LPS) increase, respectively. Therapeutic treatment of the selective melanocortin peptides 
BMS-470539 dihydrochloride and PG-990 caused a 1.9-fold ±0.04 and 2.0-fold ±0.03 
(P≤0.001 vs LPS) increase in HO-1 expression respectively (Fig. 7B), again abrogating LPS-
induced reductions of HO-1 expression and increasing levels above control. 
 
4. DISCUSSION 
We report the effects of prophylactic and therapuetic administration of melanocortin peptides 
on cell viability, pro-inflammatory cytokines, MMPs and anti-inflammatory pro-resolving, 
HO-1 following LPS activation of C-20/A4 human chondrocytes. Chondrocyte cell survival 
is pivitol in OA, being the only cell type within cartilage and having limited capacity for 
replication and being solely responsible for the synthesis and maintenance of the extraceullar 
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matrix (Grässel et al., 2009). A shift towards a catabolic phenotype over an anabolic one 
leads to increased chondrocyte death and burden on surviving cells to maintain normal matrix 
turnover. Understanding the role-played by endogenous compounds that maintain a balance 
between catabolic and anabolic processes within the joint is therefore of interest. In this study 
the pan-melanocortin agonist α-MSH, human melanocortin MC3 receptor agonist [DTrp8]-γ-
MSH, C-terminal peptide α-MSH11-13(KPV), selective human melanocortin MC1 and MC3 
receptors agonists BMS-470539 dihydrochloride and PG-990 displayed chondroprotection 
and abrogated LPS induced IL-6, IL-8, MMP-1, MMP-3 and MMP-13, and induced the pro-
resolving anti-inflammatory protein HO-1. 
 
A number of mediators released from chondrocytes include IL-1β, IL-6 and IL-8 are 
implicated in OA (Kaneva et al., 2012) and drive the inflammatory response leading to pro-
catabolic in-balance within the joint. Chondrocyte apoptosis and degradation of the articular 
cartilage matrix occur by IL-8 (Grässel et al., 2009; Chauffier et al., 2012), MMP-1 and 
MMP-13 (Goldring et al., 2011; Kaneva et al., 2012; 2014) with murine MMP13 knockdown 
demonstrating a decrease in OA development (Yoon et al., 2008) is of particular interest. 
Therefore, determining if melanocortin peptides display anti-inflammatory and pro-resolving 
effects in LPS activated chondrocytes were evaluated.  
 
Numerous studies have highlighted the potential for development of melanocortin peptides 
for modulating the inflammatory response, including the non-selective pan agonists α-MSH 
and NDP-α-MSH displaying anti-inflammatory, anti-pyretic effects (Ahmed et al., 2013; 
Patruno et al., 2018), whilst, more selective compounds [DTrp8]-γ-MSH (Kaneva et al., 2012; 
Patruno et al., 2018), BMS-470539 dihydrochloride (Leoni et al., 2010; Holloway et al., 
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2015) and AP214 (Montero-Melendez et al., 2011) modulate inflammatory responses in 
primary chondrocytes (Capsoni et al., 2015), experimental inflammatory arthritis (Patel et al., 
2010), and ischaemic reperfusion injury (Holloway et al., 2015), exerting their effects via 
human melanocortin MC1 and MC3 receptors via adenylate cyclase as demonstrated here and 
in agreement with Kaneva et al., 2012 for α-MSH and [DTrp8]-γ-MSH, whilst inhibiting pro-
inflammatory, tissue destructive mediators and inducing pro-resolving anti-inflammatory 
proteins (including IL-10) (Kaneva et al., 2012), HO-1 (Mawatari et al., 2013) and clearance 
of apoptotic neutrophils (Patruno et al., 2018). In spite of the potential of melanocortin 
peptides in modulating inflammation elicited by LPS (Sun et al., 2017), no studies to date 
have evaluated their effect in LPS (0.1 µg/ml) activated chondrocytes. In this study, we tested 
the hypothesis that melanocortin peptides displaying different receptor selectivities, can 
modulate LPS induced chondrocyte activation and death. 
Previous studies show that LPS causes chondrocyte death and upregulates IL-1β, IL-6, IL-8, 
MMP-1, MMP-3 and MMP-13 that play a role in cartilage degradation and arthritic 
progression. In this model, LPS caused a modest reduction in cell viability (13%) in 
agreement with other studies (Hu et al., 2018) and caused a significant increase in caspase-3 
and -7 as previously shown with TNF-α (Kaneva et al. 2012). Melanocortin compounds 
reduced caspase-3 and -7 activity when administered prophylactically as previously observed 
for α-MSH and [DTrp8]-γ-MSH (Kaneva et al., 2012) but shown for the first time with KPV, 
BMS-470539 dihydrochloride and PG-990. However, to our knowledge this is the first 
demonstration that these peptides can inhibit caspase-3 and -7 when given therapeutically. In 
addition, LPS activation led to elevations in IL-1β (Ni et al., 2019), IL-6, IL-8, MMP-1, 
MMP-3 and MMP-13 (Chen et al., 2013), leading to destruction of extracellular matrix and 
chondrocyte apoptosis via caspase 3 and 7 (Goldring et al., 2011; Kaneva et al., 2012), whilst 
IL-1β causes synovial inflammation and OA progression (Ni et al., 2019), upregulating the 
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disintegrin and metalloproteinases with thrombospondin motifs (ADAMTS)-4 and 
ADAMTS-5 (Zhang et al., 2018). A role for human melanocortin MC1 and/or MC3 receptors 
in modulating cell death, pro-inflammation and tissue destructive mediators has previously 
been seen (Kaneva et al., 2012, 2014). In this model, prophylactic and therapeutic treatments 
with α-MSH, [DTrp8]-γ-MSH, KPV, BMS-470539 dihydrochloride and PG-990, in the 
presence of LPS, led to a significant increase in cell viability, abrogating the LPS induced 
cell death. Whilst, prophylactic chondroprotective effects were observed with α-MSH and 
[DTrp8]-γ-MSH (Kaneva et al., 2012), we report for the first time the therapeutic effect of 
these agonists on LPS induced cell death. Moreover, we report for the first time that both 
prophylactic and therapeutic administration of the C-terminal peptide KPV (Luger and 
Brzoska 2007), BMS-470537 dihydrochloride and PG-990, display chondroprotection 
opening up new avenues for targeting OA. 
 
Following determination of the peptides chondroprotective effects, the peptides in the 
presence of LPS was evaluated against OA markers. LPS stimulation of C-20/A4 
chondrocytes led to increases in IL-1β, IL-6, IL-8, MMP-1, MMP-3 and MMP-13 as 
previously seen in rat (Chen et al., 2013; Hu et al., 2018) and human chondrocytes (Mawatari 
et al., 2013; Ni et al., 2019). LPS causes a significant upregulation of TNF-α and IL-
1β (Chen et al., 2013; Ni et al., 2019), upregulating MMPs gene expression and pro-
inflammatory cytokine, driving apoptosis via the effector caspases, causing cartilage 
degradation (Kaneva et al., 2012, 2014). Prophylactic treatment with the peptides inhibited 
expression of IL-1β, IL-6 and IL-8 as previously seen with α-MSH and [DTrp8]-γ-MSH 
(Kaneva et al., 2012, 2014). The high degree of inhibition of mRNA pro-inflammatory 
cytokine expression is reported for the first time following therapeutic treatment, highlighting 
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the ability of certain melanocortin peptides to modulate NF-κB signalling pathways 
following LPS chondrocyte activation (Huang and Kraus, 2016). Pro-inflammatory cytokine 
inhibition was observed with melanocortin peptides inhibiting IL-1β, IL-6 and IL-8 both 
prophylactically and therapeutically. However, therapeutic treatment with KPV 
(Kannengiesser et al., 2008; Land, 2012) was not as effective as α-MSH, [DTrp8]-γ-MSH, 
BMS-470539 dihydrochloride and PG-990 on IL-6 and IL-8 as previously observed (Capsoni 
et al., 2015). With respect to IL-6 and IL-8, KPV demonstrated a reduced anti-inflammatory 
effect in this study even though it has previously been shown to have similar effects to α-
MSH on elevated intracellular calcium fluxes (Brzoska et al., 2008). In a study in rabbits 
central effects of KPV were more pronounced than peripheral administration with effects less 
than α-MSH (Richards and Lipton 1984) suggesting that full activity requires other regions 
of the hormone (HFRW). However, for IL-1β, KPV appeared to cause a similar degree of 
inhibition as α-MSH both  prophylactically and therapeutically and could be due to the fact 
that the L form of K(D)PT is similar to IL-1β193-195 and is well tolerated in ulcerative colitis 
(Kucharzik et al., 2017).  
Given the increase in pro-inflammatory mediators by LPS stimulation and their reduction by 
the melanocortin peptides, the effect of the peptides on MMPs was evaluated. MMP-1, 
MMP-3, and MMP-13 was reduced following prophylactic administration confirming 
previous findings with α-MSH and [DTrp8]-γ-MSH (Goldring et al., 2011, Kaneva et al., 
2012, 2014). However, a novel finding was observed for KPV (MMP-1 and MMP-13), BMS-
470539 dihydrochloride (MMP-1, MMP-3 and MMP-13) and PG-990 (MMP-1, MMP-3 and 
MMP-13). Another exciting novel observation was the ability of therapeutic treatments with 
α-MSH, [DTrp8]-γ-MSH and PG-990 to significantly reduce MMP-1, MMP-3 and MMP-13 




In the final section, we investigated the effect of these peptides on induction of the anti-
inflammatory pro-resolving protein HO-1. Previous studies show α-MSH, [DTrp8]-γ-MSH, 
human melanocortin MC3/4 receptor agonist MTII increased the anti-inflammatory protein 
IL-10 (Lam et al., 2005a, Kaneva et al., 2012). The importance of this mediator was 
demonstrated in healthy primary human chondrocytes, whereby IL-10 was proposed to be the 
mechanism of action for chondroprotection reducing both MMP1 and MMP13 gene 
expression (Muller et al., 2008; Li et al., 2017). Thus, developing compounds that can induce 
pro-resolving mediators is an exciting proposal. Here, we determined whether these peptides 
could induce HO-1, previously shown to be upregulated by ACTH, MTII (Lam et al., 2005b) 
and α-MSH in cardiovascular tissue (Vecsernyes et al., 2017) and a model of retinal damage 
(Rossi et al., 2016). LPS reduced the expression of the anabolic protein HO-1, as previously 
seen (Mawatari et al., 2013; Kaneva et al., 2014) and supports a plausible explanation of why 
elevations in the catabolic proteins IL-1β, IL-6, IL-8, MMP-1, MMP-3 and MMP-13 occur. 
Here we report for the first time that prophylactic and therapeutic treatment with the peptides, 
reversed the inhibition of HO-1 expression by LPS, highlighting the potent anti-inflammatory 
properties of these peptides. Therefore, the ability of these peptides to signal via HO-1 is an 
exciting observation in chondrocytes for resolving chondrocyte born pro-inflammatory 
cytokines and MMPs production in the development of arthritic pathologies. 
 
5. Conclusion 
The panel of melanocortin peptides selected for this investigation attenuated the effects 
caused by LPS at both the molecular and biochemical level. It was observed that the human 
melanocortin MC3 receptor agonists [DTrp8]-γ-MSH and PG-990 inhibited pro-inflammatory 
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cytokine and MMP release to a greater degree than that observed with the human 
melanocortin MC1 receptor agonists BMS-470539 dihydrochloride and C-terminal KPV 
when administered prophylactically and therapeutically, suggesting a more prominent role for 
the human melanocortin MC3 receptor. Evaluating the pro-resolution effects of these 
peptides demonstrated that [DTrp8]-γ-MSH and PG-990 induced HO-1 and exhibited a 
greater degree of chondroprotection compared to the more human melanocortin MC1 
receptor selective compounds. However, given the protective effects of these peptides 
targeting both human melanocortin MC1 and MC3 receptors may potentially provide the best 
therapeutic strategy as observed with AP214, which is in clinical development for acute 
kidney injury. Whilst it’s important to highlight the beneficial effects of peptide therapy with 
around 150 in current drug development pipelines, we are mindful that a number of issues 
that exist with this approach, namely oral bioavailability which may limit patient compliance 
(Lau and Dunn 2018). They are also prone to hydrolysis and oxidation, short half-life and fast 
elimination, there are also potential threats of immunogenicity (Fosgerau and Hoffmann, 
2015). However, they have the advantage of good efficacy, safety and tolerability and 
predictable metabolism (Fosgerau and Hoffmann 2015). In addition, there are a number of 
peptides commercially used e.g. Insulin, ACTH (parent hormone of melanocortin peptides) as 
well as the target for human melanocortin MC1 receptor, Afamelanotide (Melanotan 1) used 
for erythropoietic protoporphyria (Lau and Dunn 2018). Therefore, development of 
appropriate drug delivery systems, formulation and improvement in half-life will enhance 
their biological use. This data, thus further enhances our knowledge of melanocortin peptides 
in arthritic pathologies highlighting their ability to work both prophylactically and 
therapeutically. 
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Figure legends 
Fig.1. Effect of α-MSH, [Dtrp8]-γ-MSH, KPV, BMS-470539 and PG-990 on Caspase 3/7 
activity on LPS activated C-20/A4 chondrocytes. C-20/A4 chondrocytes were plated at 2.0 
x 103 cells/well. Panel A - chondrocytes treated with PBS, α-MSH (3.0  µg/ml), [Dtrp8]-γ-
MSH (3.0  µg/ml) or KPV (4.0  µg/ml) for 30 min prior to stimulation with LPS (0.1 µg/ml) 
for 6 h (prophylactic treatment) or stimulated with LPS (0.1 μg/ml) for 2 h followed by 
melanocortin peptide treatment for a further 4 h (therapeutic treatment). Panel B, 
chondrocytes treated with PBS, BMS-470539 dihydrochloride (10.0  µg/ml) or PG-990 (3.0 
 µg/ml) for 30 min prior to stimulation with LPS (0.1 µg/ml) for 6 h (prophylactic treatment) 
or stimulated with LPS (0.1 μg/ml) for 2 h followed by melanocortin peptide treatment for a 
further 4 h (therapeutic treatment). After 6 h, Caspase 3/7 activity was determined by 
Caspase-3/7 Glo Assay. Dotted line symbolises Caspase 3/7 activity following PBS treatment 
(control). Data are presented as Mean ± S.E.M of n = 3 samples repeated in triplicate. **P≤ 




Fig. 2. Effect of prophylactic and therapeutic administration of melanocortin peptides 
on IL6 and IL8 gene expression from C-20/A4 cells stimulated with LPS (0.1 µg/ml) for 
6 h. C-20/A4 chondrocytes were treated with α-MSH (3.0 µg/ml), [DTrp8]-γ-MSH (3.0 
µg/ml) or KPV (4.0 µg/ml) for 30 min prior to LPS (0.1 µg/ml) stimulation for 6 h 
(prophylactic treatment) or stimulated with LPS (0.1 µg/ml) for 2 h followed by α-MSH (3.0 
µg/ml), [DTrp8]-γ-MSH (3.0 µg/ml) or KPV (4.0 µg/ml) treatment for a further 4 h 
(therapeutic treatment),  total RNA extracted 6 h post stimulation. PCR amplification with the 
respective primers for IL6 and IL8 was used to detect and quantify gene expression on 2% 
agarose gels with β-actin used as internal control, experiment repeated in triplicate (Panel A). 
Comparison of densitometrically quantified IL6 and IL8 gene expression (Panel B and C) 
shown in arbitrary units, each value normalised to the respective β-actin expression. Data are 
presented as mean values ± S.E.M of n = 3 samples, experiment repeated in triplicate, #P≤ 
0.05, ##P≤ 0.01, ###P≤ 0.001 vs untreated controls or *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001 vs LPS 
(0.1 µg/ml). 
 
Fig. 3. Effect of prophylactic and therapeutic administration of melanocortin peptides 
on MMP1, MMP3 and MMP13 gene expression from C-20/A4 cells stimulated with LPS 
(0.1 µg/ml) for 6 h. C-20/A4 chondrocytes were treated with α-MSH (3.0 µg/ml), [DTrp8]-γ-
MSH (3.0 µg/ml) or KPV (4.0 µg/ml) for 30 min prior to LPS (0.1 µg/ml) stimulation for 6 h 
(prophylactic treatment) or stimulated with LPS (0.1 µg/ml) for 2 h followed by α-MSH (3.0 
µg/ml), [DTrp8]-γ-MSH (3.0 µg/ml) or KPV (4.0 µg/ml) treatment for a further 4 h 
(therapeutic treatment), total RNA extracted 6 h post stimulation. PCR amplification with the 
respective primers for MMP1, MMP3 and MMP13 was used to detect and quantify gene 
expression on 2% agarose gels with β-actin used as internal control, experiment repeated in 
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triplicate (Panel A). Comparison of densitometrically quantified MMP1, MMP3 and MMP13 
gene expression (Panel B, C and D) shown in arbitrary units, each value normalised to the 
respective β-actin expression. Data are presented as mean values ± S.E.M of n = 3 samples, 
experiment repeated in triplicate, #P≤ 0.05, ##P≤ 0.01, ###P≤ 0.001 vs untreated controls or *P≤ 
0.05, **P≤ 0.01, ***P≤ 0.001 vs LPS (0.1 µg/ml). 
 
Fig. 4.  Effect of prophylactic and therapeutic administration of α-MSH, [DTrp8]-γ-
MSH and KPV in LPS activated C-20/A4 cells on HO-1 expression. A representative 
western blot of three individual experiments of cells treated with PBS (control), LPS 
0.1µg/ml alone or in combination with α-MSH (3.0 µg/ml), [DTrp8]-γ-MSH (3.0 µg/ml) or 
KPV (4.0 µg/ml) for 6 h (both prophylactic and therapeutic treatment). Western blotting was 
used to determine HO-1 and α-tubulin using protein levels using rabbit anti-HO-1 (1:2000). 
Bands with sizes corresponding to HO-1 (32 kDa) and α-tubulin (55 kDa) were detected 
(Panel A) and densitometrically quantified (Panel B). Data are presented as mean values ± 
S.E.M of n = 3 samples, experiment repeated in triplicate, #P≤ 0.05, ##P≤ 0.01, ###P≤ 0.001 vs 
untreated controls or *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001 vs LPS (0.1 µg/ml). 
 
Fig. 5. Effect of prophylactic and therapeutic administration of selective human 
melanocortin MC1 and MC3 receptor agonists BMS-470539 dihydrochloride and PG-
990  on IL6 and IL8 gene expression from C-20/A4 cells activated by LPS (0.1 µg/ml) for 
6 h. C-20/A4 chondrocytes were treated with selective human melanocortin MC1 receptor 
agonist BMS-470539 dihydrochloride (BMS; 10.0 µg/ml) or selective human melanocortin 
MC3 receptor agonist PG-990 (3.0 µg/ml) for 30 min prior to LPS (0.1 µg/ml) stimulation for 
6 h (prophylactic treatment) or stimulated with LPS (0.1 µg/ml) for 2 h followed by BMS-
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470539 dihydrochloride (BMS; 10.0 µg/ml) or PG-990 (3.0 µg/ml) treatment for a further 4 h 
(therapeutic treatment), total RNA extracted 6 h post stimulation. PCR amplification with the 
respective primers for IL6 and IL8 was used to detect and quantify gene expression on 2% 
agarose gels with β-actin used as internal control, experiment repeated in triplicate (Panel A). 
Comparison of densitometrically quantified IL6 and IL8 gene expression (Panel B and C) 
shown in arbitrary units, each value normalised to the respective β-actin expression. Data are 
presented as mean values ± S.E.M of n = 3 samples, experiment repeated in triplicate, #P≤ 
0.05, ##P≤ 0.01, ###P≤ 0.001 vs untreated controls or *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001 vs LPS 
(0.1 µg/ml).  
 
Fig. 6. Effect of prophylactic and therapeutic administration of selective human 
melanocortin MC1 and MC3 receptor agonists BMS-470539 dihydrochloride and PG-
990  on MMP1, MMP3 and MMP13 gene expression from C-20/A4 cells activated by 
LPS (0.1 µg/ml) for 6 h. C-20/A4 chondrocytes were treated with selective human 
melanocortin MC1 receptor agonist BMS-470539 dihydrochloride (BMS; 10.0 µg/ml) or 
human melanocortin MC3 receptor agonist PG-990 (3.0 µg/ml) for 30 min prior to LPS (0.1 
µg/ml) stimulation for 6 h (prophylactic treatment) or stimulated with LPS (0.1 µg/ml) for 2 h 
followed by BMS-470539 dihydrochloride (BMS; 10.0 µg/ml) or PG-990 (3.0 µg/ml) 
treatment for a further 4 h (therapeutic treatment), total RNA extracted 6 h post stimulation. 
PCR amplification with the respective primers for MMP1, MMP3 and MMP13 was used to 
detect and quantify gene expression on 2% agarose gels with β-actin used as internal control, 
experiment repeated in triplicate (Panel A). Comparison of densitometrically quantified 
MMP1, MMP3 and MMP13 gene expression (Panel B) shown in arbitrary units, each value 
normalised to the respective β-actin expression. Data are presented as mean values ± S.E.M 
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of n = 3 samples, experiment repeated in triplicate, #P≤ 0.05, ##P≤ 0.01, ###P≤ 0.001 vs 
untreated controls or *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001 vs LPS (0.1 µg/ml). 
 
Fig. 7.  Effect of prophylactic and therapeutic administration of selective human 
melanocortin MC1 and MC3 receptor agonists BMS-470539 dihydrochloride and PG-
990 in LPS activated C-20/A4 cells on HO-1 expression. A representative western blot of 
three individual experiments of cells treated with PBS (control), LPS 0.1µg/ml alone or in 
combination with BMS-470539 dihydrochloride (BMS; 10.0 µg/ml) or PG-990 (3.0 µg/ml) 
for 6h (both prophylactic and therapeutic treatment). Western blotting was used to determine 
HO-1 and α-tubulin using protein levels using rabbit anti-HO-1 (1:2000). Bands with sizes 
corresponding to HO-1 (32 kDa) and α-tubulin (55 kDa) were detected (Panel A) and 
densitometrically quantified (Panel B). Data are presented as mean values ± S.E.M of n = 3 
samples, #P≤ 0.05, ##P≤ 0.01, ###P≤ 0.001 vs untreated controls or *P≤ 0.05, **P≤ 0.01, ***P≤ 
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